We are live on ! Find out more
FHTX icon

Foghorn Therapeutics
FHTX

47 hedge funds and large institutions have $338M invested in Foghorn Therapeutics in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

33% more capital invested

Capital invested by funds: $255M → $338M (+$83.2M)

21% more funds holding

Funds holding: 39 → 47 (+8)

0.85% more ownership

Funds ownership: 64.88% → 65.73% (+0.85%)

29% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 14

Holders
47
Holders Change
+8
Holders Change %
+20.51%
% of All Funds
0.82%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
11
Increased
10
Reduced
14
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
KCM
Kingdon Capital Management
New York
+$2.28M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.73M
3
PVI
Pura Vida Investments
New York
+$754K
4
JGC
J. Goldman & Co
New York
+$747K
5
State Street
State Street
Massachusetts
+$394K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$1.14M
2
Deutsche Bank
Deutsche Bank
Germany
-$1.04M
3
Charles Schwab
Charles Schwab
California
-$237K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$225K
5
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS)
California
-$173K
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$177M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$35.1M -$225K -20,300 -0.8%
AG
3
Artal Group
Luxembourg
$24M – – –
EC
4
Euclidean Capital
New York
$17.6M – – –
BlackRock
5
BlackRock
New York
$15.6M +$286K +25,825 +2%
Morgan Stanley
6
Morgan Stanley
New York
$13.6M -$10.9K -982 -0.1%
Vanguard Group
7
Vanguard Group
Pennsylvania
$11.7M +$1.73M +156,139 +23%
MIM
8
Monashee Investment Management
Massachusetts
$7.39M – – –
AI
9
Alphabet Inc
California
$6.98M – – –
BC
10
Birchview Capital
Vermont
$4.38M – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$3.8M +$387K +34,963 +15%
State Street
12
State Street
Massachusetts
$3.13M +$394K +35,621 +19%
CC
13
Casdin Capital
New York
$3M -$13.5K -1,216 -0.6%
KCM
14
Kingdon Capital Management
New York
$2.87M +$2.28M +205,741 New
Northern Trust
15
Northern Trust
Illinois
$2.44M +$135K +12,172 +7%
Deutsche Bank
16
Deutsche Bank
Germany
$1.32M -$1.04M -94,169 -50%
Millennium Management
17
Millennium Management
New York
$1.29M -$1.14M -103,129 -53%
SCM
18
Suvretta Capital Management
New York
$1.17M – – –
PVI
19
Pura Vida Investments
New York
$949K +$754K +68,095 New
JGC
20
J. Goldman & Co
New York
$940K +$747K +67,500 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$740K +$18.8K +1,699 +3%
N
22
Nuveen
North Carolina
$709K -$31.4K -2,836 -5%
Charles Schwab
23
Charles Schwab
California
$696K -$237K -21,403 -30%
HSBC Holdings
24
HSBC Holdings
United Kingdom
$284K – – –
RhumbLine Advisers
25
RhumbLine Advisers
Massachusetts
$257K +$31.2K +2,815 +18%
1
2

FHTX Hedge Fund Activity: Q3 2021 in Review

47 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q3 2021, worth a combined $338M — up 33% from $255M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new FHTX positions and 3 closed out — a net gain of 8 holders — while 10 added to existing stakes and 14 trimmed.

The largest buyer was Kingdon Capital Management, opening a new position worth an estimated $2.28M. The largest seller was Millennium Management, cutting an estimated $1.14M.

  • 47 institutional investors held Foghorn Therapeutics (FHTX) as of Q3 2021, up from 39 in Q2 2021.
  • Funds reported $338M of Foghorn Therapeutics stock for Q3 2021, up 33% quarter-over-quarter.
  • 11 funds opened new Foghorn Therapeutics positions in Q3 2021 and 3 closed out, a net change of +8 holders.
  • The largest Foghorn Therapeutics buyer in Q3 2021 was Kingdon Capital Management, an estimated $2.28M added.
  • The largest Foghorn Therapeutics seller in Q3 2021 was Millennium Management, an estimated $1.14M sold.

Based on aggregated 13F filings for Q3 2021.